How do executive changes at pharma companies signal strategy shifts?

CEO transitions often signal portfolio pivots. When Pfizer hired Albert Bourla, it preceded a shift toward mRNA and oncology. When Viatris appointed a restructuring specialist, divestitures followed within 18 months. Board-level changes at PBMs tend to precede pricing model shifts or vertical integration moves. Track the background of incoming executives to predict strategic direction.